p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.
OBJECTIVE
Autoantibodies against the p53 tumor suppressor protein have been detected in the serum of a proportion of patients with various cancers. The generation of such antibodies has been proposed to be due to either tumor p53 protein accumulation or to the type of p53 gene mutation. These hypotheses are examined in the present study.


METHODS
Using immunofluorometric assays, we studied 195 patients with primary breast cancer for the presence of p53 antibodies in serum and p53 protein accumulation in the corresponding tumor. Seventeen patients (9%) were p53 antibody-positive and 77 (40%) overexpressed p53. Ten of the 17 p53 antibody-positive patients had tumor p53 accumulation and 7 were negative for p53. Statistical analysis revealed a weak association between the presence of p53 antibodies and p53 protein accumulation (p = 0.05). Direct DNA sequencing of exons 1-11 of the p53 gene was performed for 16 p53 antibody-positive and 16 p53 antibody-negative patients.


RESULTS
Five of the seropositive and eight of the seronegative patients had a p53 gene mutation. Four of the five mutations in the p53 antibody-positive patients affected a Tyr residue, whereas none of the gene abnormalities in the seronegative patients had such an effect.


CONCLUSIONS
We conclude that p53 antibodies tend to develop in patients with tumor p53 accumulation, but p53 accumulation is neither sufficient nor necessary for the generation of the immune response. Further, p53 antibody-positive patients do not have higher frequency of p53 gene mutations than p53 antibody-negative patients, but the former patient group is associated with a Tyr substitution in the protein product.
Angelopoulou
K
K
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Yu
H
H
Bharaj
B
B
Giai
M
M
Diamandis
E P
EP
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000917:Antibody Formation; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism*; D005091:Exons / Q000235:genetics; D005260:Female; D005455:Fluorescent Antibody Technique; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000276:immunology; D017354:Point Mutation; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000276:immunology*
D001323:Autoantibodies; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53